Effect of aging on bone formation induced by recombinant human bone morphogenetic protein-2 combined with fibrous collagen membranes at subperiosteal sites.
This study was designed to examine the effect of aging on bone formation induced by recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with a fibrous collagen membrane (FCM). Implantation was done subperiosteally in bilateral palatal grooves in 34 male Wistar rats divided into three age groups: a 10-week-old group (10w group), a 30-week-old group (30w group) and a 70-week-old group (70w group). RhBMP-2-combined FCMs were implanted on the left palatal grooves as BMP-implanted sites (BMP site), while rhBMP-2 was not implanted on the right palatal grooves as control sites. The rats were sacrificed 6 weeks after implantation, and histometric evaluations were performed. New bone formation was observed in every site of each age group and the new bone was almost completely continuous with the original bone. The new bone volume (NBV) of the BMP site was significantly higher than that of the control site in each age group. The NBV of both the control and BMP sites were highest in the 10w group and lowest in the 70w group. The disparity of NBV between the control and BMP sites, which indicated the response to implanted BMP excluding the effect of skeletal growth and surgical stimulation, did not significantly differ among the age groups. These results indicate that rhBMP-2-combined FCM has the ability to induce new bone formation continuous with original bone even in senescent rats. Furthermore, it appeared that, in the case of palatal subperiosteal implantation, the responsiveness to implanted BMP was independent of age, although the total volume of newly formed bone declined with aging.
Matsumoto
A
A
Department of Oral Health Science, Graduate School of Dental Medicine, Hokkaido University, Sapporo, Japan. mats@perio2.den.hokudai.ac.jp
Yamaji
K
K
Kawanami
M
M
Kato
H
H
D000375:Aging / Q000502:physiology*; D000818:Animals; D001835:Body Weight; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D003094:Collagen; D004337:Drug Carriers; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008567:Membranes, Artificial; D010011:Osteocytes / Q000473:pathology; D010012:Osteogenesis / Q000187:drug effects* / Q000502:physiology; D010159:Palate / Q000187:drug effects* / Q000473:pathology / Q000601:surgery; D010521:Periosteum / Q000187:drug effects / Q000473:pathology / Q000601:surgery; D019736:Prostheses and Implants; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins; D018709:Statistics, Nonparametric; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000627:therapeutic use*
C525718:BMP2 protein, human; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D008567:Membranes, Artificial; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D003094:Collagen